Want to see BRKR full AI Analyst Report?
BRKR Stock Chart & Stats
$57.06
-$0.40(-0.66%)
At close: 4:00 PM EDT
$57.06
-$0.40(-0.66%)
Day’s Range― - ―
52-Week Range$32.37 - $66.98
Previous Close$60.45
Volume1.84M
Average Volume (3M)2.26M
Market Cap
$8.44B
Enterprise Value$10.82B
Total Cash (Recent Filing)$184.90M
Total Debt (Recent Filing)$1.92B
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Oct 29, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend Yield0.36%
Share Statistics
EPS (TTM)-0.70
Shares Outstanding152,359,310
10 Day Avg. Volume2,199,997
30 Day Avg. Volume2,257,854
Financial Highlights & Ratios
PEG Ratio2.62
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio514.48
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit6.62
Enterprise Value/Ebitda43.69
Forecast
1Y Price Target
$61.33Price Target Upside7.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)2.12
Revenue Forecast (FY)$3.56B
Bulls Say, Bears Say
Bulls Say
Recurring Installed-base RevenueBruker combines upfront instrument sales with recurring service, software and consumables revenue tied to a long-lived installed base. This model can improve customer retention, increase lifetime value, and provide a more durable revenue foundation than relying only on replacement cycles.
Strong Scientific-instrument BookingsSustained bookings growth and a book-to-bill ratio above one indicate demand is replenishing the order pipeline rather than merely drawing down backlog. If maintained, this supports future revenue visibility, reinforces Bruker's market position, and can improve operating leverage.
Cost Savings And Margin RecoveryThe scale and multi-year nature of the cost program provide a tangible basis for restoring profitability after recent margin compression. Executed savings can support operating-margin expansion, strengthen cash generation, and create flexibility to invest in products and connected workflows.
Bears Say
Sharp Profitability DeteriorationThe move from consistent profits to losses and low-single-digit EBIT margins weakens internal funding capacity and makes earnings recovery central to the investment case. Persistent margin pressure could reduce the benefit of revenue growth and constrain investment, deleveraging, and shareholder returns.
Regional And End-market WeaknessWeakness across China, broader Asia Pacific, and U.S. academic and government customers exposes Bruker to uneven research funding and regional demand. Prolonged softness could delay instrument purchases, weigh on segment utilization, and make consolidated growth and margin improvement less dependable.
Long Conversion Cycle For Deep-tech OrdersLong delivery and revenue-recognition cycles reduce the near-term conversion of strong bookings into reported sales and earnings. This creates greater timing uncertainty, keeps quarterly results dependent on backlog execution, and delays the cash-flow and margin benefits expected from deep-tech demand.
Bruker News
BRKR FAQ
What was Bruker Corp’s price range in the past 12 months?
Bruker Corp lowest stock price was $32.37 and its highest was $66.98 in the past 12 months.
What is Bruker Corp’s market cap?
Bruker Corp’s market cap is $8.44B.
When is Bruker Corp’s upcoming earnings report date?
Bruker Corp’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were Bruker Corp’s earnings last quarter?
Bruker Corp released its earnings results on Aug 04, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.385 by $0.105.
Is Bruker Corp overvalued?
According to Wall Street analysts Bruker Corp’s price is currently Undervalued.
Does Bruker Corp pay dividends?
Bruker Corp pays a Quarterly dividend of $0.05 which represents an annual dividend yield of 0.36%. See more information on Bruker Corp dividends here
What is Bruker Corp’s EPS estimate?
Bruker Corp’s EPS estimate is 0.42.
How many shares outstanding does Bruker Corp have?
Bruker Corp has 152,359,310 shares outstanding.
What happened to Bruker Corp’s price movement after its last earnings report?
Bruker Corp reported an EPS of $0.49 in its last earnings report, beating expectations of $0.385. Following the earnings report the stock price went down -21.784%.
Which hedge fund is a major shareholder of Bruker Corp?
Currently, no hedge funds are holding shares in BRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bruker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.33 (7.49% Upside)
$61.33 (7.49% Upside)
Blogger Sentiment
Neutral
BRKR Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $197.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.36%
12-Months-Change
Fundamentals
Return on Equity
-2.92%
Trailing 12-Months
Asset Growth
-4.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bruker Corp
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
BRKR Company Deck
BRKR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed material operational and financial progress — notably a return to organic growth in Q2, substantial margin expansion, double-digit non-GAAP EPS growth, strong deep-tech and semiconductor bookings, and confirmed cost-savings execution and year guidance. However, material lowlights included a $135M goodwill impairment leading to a GAAP loss, lingering weakness in U.S. academic/government spending, regional softness in China and APAC, timing-related revenue recognition delays from longer lead-time deep tech orders, and FX/tariff headwinds. On balance the positive momentum in bookings, margins, cash flow and cost savings, along with maintained FY guidance, outweigh the notable one-time impairment and near-term timing/currency headwinds.View all BRKR earnings summariesBRKR Stock 12 Month Forecast
Average Price Target
$61.33
▲(7.49% Upside)
Technical Analysis
Bio-Rad Laboratories
―
Pacific Biosciences
―
Quanterix
―
Cytek Biosciences
―
GE Healthcare Technologies Inc
―
Ownership Overview
27.13% Insiders
24.12% Mutual Funds
0.17% Other Institutional Investors
29.73% Public Companies and
Individual Investors